Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
Passage Bio (PASG) Stock Price & Analysis
314 Followers
PASG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.58 - $1.92
Previous Close$0.62
Volume644.98K
Average Volume (3M)206.92K
Market Cap
$33.99M
Enterprise Value-$72.27M
Total Cash (Recent Filing)$132.78M
Total Debt (Recent Filing)$26.52M
Price to Earnings (P/E)-0.3
Beta1.25
Next Earnings
Feb 29, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding54,819,638
10 Day Avg. Volume299,900
30 Day Avg. Volume206,920
Standard Deviation0.19
R-Squared0.09
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.27
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.65
Forecast
1Y Price Target
$7.00Price Target Upside862.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Passage Bio News
Pre-EarningsPassage Bio, Inc. (PASG) Q3 Earnings Cheat Sheet
Ownership Overview
0.00% Insiders
5.87% Mutual Funds
47.05% Other Institutional Investors
47.08% Public Companies and
Individual Investors
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $0.57 and its highest was $1.92 in the past 12 months.
What is Passage Bio’s market cap?
Currently, no data Available
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is Feb 29, 2024 which is in 92 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on Nov 13, 2023. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.457 by -$0.033.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -$0.42.
How many shares outstanding does Passage Bio have?
Passage Bio has 54,819,637 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.457. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Passage Bio?
Among the largest hedge funds holding Passage Bio’s share is Versant Venture Management, LLC. It holds Passage Bio’s shares valued at 3M.
---
Passage Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (862.33% Upside)
$7.00 (862.33% Upside)
Blogger Sentiment
Bullish
PASG Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.56%
12-Months-Change
Fundamentals
Return on Equity
-64.09%
Trailing 12-Months
Asset Growth
-37.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Passage Bio
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
---
Top 5 ETFs holding PASG
Vanguard Total Stock Market ETF
$957.81K
Up to five ETFs with an Outperform Smart Score that hold PASG. The ETFs are listed according to market value of PASG within the ETF
---